Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market
Branded Legacy (OTC:BLEG) announced that its subsidiary BioLegacy has filed a provisional patent for an innovative air-driven intranasal drug delivery platform. The technology features a thumb-sized, single-use device that delivers precise intranasal dosing for both stable liquid formulations and drugs requiring reconstitution.
The platform's key innovations include an air-driven precision delivery system, dual-function architecture, unitary blow-fill-seal construction, and sequential frangible membranes. The device is specifically designed to improve the delivery of medications like naloxone for opioid overdose reversal, targeting enhanced accessibility and affordability in emergency scenarios.
The development aligns with BioLegacy's recent acquisition of a GMP-compliant manufacturing facility with ISO Class 7 & 8 cleanrooms, and ongoing R&D collaborations with McMaster University and Stanford University.
Branded Legacy (OTC:BLEG) ha annunciato che la sua controllata BioLegacy ha presentato una domanda provvisoria di brevetto per una piattaforma innovativa di somministrazione intranasale guidata dall’aria. La tecnologia prevede un dispositivo monouso di grandezza pollice che consente dosi intranasali con precisione sia per formulazioni liquide stabili sia per farmaci che necessitano di ricostituzione.
Le principali innovazioni della piattaforma includono un sistema di erogazione di precisione guidato dall’aria, un’architettura a doppia funzione, una costruzione unitaria blow-fill-seal e membrane frangibili sequenziali. Il dispositivo è pensato per migliorare la somministrazione di farmaci come la naloxone per la reversal delle overdose da oppioidi, con l’obiettivo di aumentare accessibilità e convenienza in scenari di emergenza.
Lo sviluppo è in linea con l’acquisizione recente da parte di BioLegacy di un impianto di produzione conforme GMP con camere pulite ISO Classe 7 e 8, e con collaborazioni R&D in corso con la McMaster University e l’Università di Stanford.
Branded Legacy (OTC:BLEG) anunció que su subsidiaria BioLegacy ha presentado una solicitud de patente provisional para una innovadora plataforma de administración intranasal impulsada por aire. La tecnología cuenta con un dispositivo desechable del tamaño de un pulgar que realiza dosis intranasales con precisión, para formulaciones líquidas estables y fármacos que requieren reconstitución.
Las innovaciones clave de la plataforma incluyen un sistema de entrega de precisión impulsado por aire, arquitectura de doble función, construcción unitaria blow-fill-seal y membranas frangibles secuenciales. El dispositivo está diseñado específicamente para mejorar la administración de medicamentos como la naloxona para revertir sobredosis por opioides, buscando mayor accesibilidad y asequibilidad en escenarios de emergencia.
El desarrollo se alinea con la reciente adquisición por BioLegacy de una instalación de fabricación conforme a GMP con salas limpias ISO Clase 7 y 8, y con colaboraciones de I+D en curso con la McMaster University y la Stanford University.
Branded Legacy (OTC:BLEG)가 자회사 BioLegacy가 공기 구동 비경구 투여 플랫폼에 대한 임시 특허를 출원했다고 발표했습니다. 이 기술은 한 손가락 크기의 일회용 기기를 특징으로 하며 안정된 액상 제형과 재구현이 필요한 약물을 위한 정밀 비경구 투여를 제공합니다.
플랫폼의 주요 혁신은 공기 구동 정밀 전달 시스템, 이중 기능 아키텍처, 단일 블로-필-씰 구조, 순차적으로 파손 가능한 멤브레인으로 구성되어 있습니다. 이 기기는 오피오이드 과다복용을 역전시키는 나록손과 같은 약물의 전달을 개선하도록 특별히 설계되어 응급 상황에서의 접근성과 비용 효율성을 높이는 것을 목표로 합니다.
이 개발은 GMP 규격의 제조 시설을 확보한 BioLegacy의 최근 인수 및 ISO Class 7 & 8 청정실과 McMaster University 및 Stanford University와의 R&D 협력과 함께 진행 중입니다.
Branded Legacy (OTC:BLEG) a annoncé que sa filiale BioLegacy a déposé une demande de brevet provisoire pour une plateforme innovante de délivrance intranasale pilotée par l’air. La technologie présente un dispositif jetable de la taille d’un pouce qui délivre des doses intranasales avec précision, pour des formulations liquides stables et des médicaments nécessitant une reconstitution.
Les innovations clés de la plateforme incluent un système de délivrance de précision piloté par l’air, une architecture à double fonction, une construction unitaire blow-fill-seal et des membranes fragiles séquentielles. Le dispositif est spécifiquement conçu pour améliorer l’administration de médicaments comme la naloxone afin d’inverser les overdoses d’opioïdes, en visant une meilleure accessibilité et une plus grande facilité d’utilisation en situation d’urgence.
Le développement s’aligne avec l’acquisition récente par BioLegacy d’une installation de fabrication conforme GMP avec des salles propres ISO Classe 7 & 8, et des collaborations R&D en cours avec McMaster University et l’Université de Stanford.
Branded Legacy (OTC:BLEG) gab bekannt, dass seine Tochtergesellschaft BioLegacy eine vorläufige Patentanmeldung für eine innovative luftbetriebene intranasale Medikamentenabgabesplattform eingereicht hat. Die Technologie verfügt über ein Daumen großes, Einweg-Gerät, das präzise intranasale Dosen sowohl für stabile flüssige Formulierungen als auch für Arzneimittel, die rekonstruiert werden müssen, liefert.
Die zentralen Innovationen der Plattform umfassen ein luftgetriebenes Präzisions-Abgabesystem, eine Dual-Funktions-Architektur, eine einheitliche Blow-Fill-Seal-Konstruktion und sequentielle zerbrechliche Membranen. Das Gerät ist speziell darauf ausgerichtet, die Verabreichung von Medikamenten wie Naloxon zur Umkehr einer Opioid-Überdosierung zu verbessern, mit dem Ziel, die Zugänglichkeit und Erschwinglichkeit in Notfallsituationen zu erhöhen.
Die Entwicklung steht im Einklang mit der jüngsten Übernahme einer GMP-konformen Herstellungsanlage durch BioLegacy sowie ISO Class 7 & 8 Saubere Räumen und laufenden F&E-Kooperationen mit der McMaster University und der Stanford University.
Branded Legacy (OTC:BLEG) أعلـنت أن شركة BioLegacy التابعة لها قد قدمت طلب براءة اختراع مؤقتة لمنصة توصيل دواء داخل الأنف مدفوعة بالهواء ومبتكرة. تتميز التكنولوجيا بجهاز أحادي الاستخدام بحجم الإصبع يتيح جرعات أنفية دقيقة لكل من التركيبات السائلة المستقرة والأدوية التي تتطلب إعادة التركيب.
تشمل الابتكارات الرئيسية للمنصة نظام توصيل دقيق مدفوع بالهواء وهندسة ذات وظيفتين وبناء Blow-Fill-Seal موحد واغشية قابلة للكسر بالتتابع. صُمم الجهاز خصيصاً لتحسين توصيل أدوية مثل النالوكسان لإنعاش حالات التسمم بالأفيونيات، مستهدفاً زيادة الوصولية والقدرة على التحمل في سيناريوهات الطوارئ.
يتماشى التطوير مع استحواذ BioLegacy الأخير على منشأة تصنيع مطابقة لمعايير GMP مع حجرات نظيفة ISO Class 7 و8، وبالتعاون البحثي والتطويري الجاري مع جامعة مكرستر وجامعة ستانفورد.
Branded Legacy (OTC:BLEG) 宣布其子公司 BioLegacy 已就一项创新的空气驱动鼻腔给药平台提交了临时专利申请。该技术特点是一个拇指大小的一次性设备，可为稳定液态制剂以及需要重配的药物提供精确的鼻腔给药。
该平台的关键创新包括一个空气驱动的精密给药系统、双功能架构、统一的 Blow-Fill-Seal 结构，以及序列性易碎膜。该设备专门设计用于改进如纳洛酮等药物的给药，以用于阿片类药物过量逆转，目标是在紧急场景中提升可及性与可负担性。
这一开发与 BioLegacy 最近收购的符合 GMP 的制造设施，以及具 ISO Class 7 与 8 洁净室的条件相一致，并与麦克马斯特大学和斯坦福大学在研发领域开展合作。
- Filing of provisional patent for innovative intranasal drug delivery platform
- Device compatible with both stable solutions and reconstitutable medications
- Cost-effective manufacturing through unitary blow-fill-seal construction
- Strategic alignment with recently acquired GMP-compliant manufacturing facility
- Ongoing R&D collaborations with prestigious institutions (McMaster and Stanford)
- Patent is still in provisional stage, pending full approval
- Product yet to receive regulatory approvals from Health Canada and FDA
- Technology still in development phase without proven market success
Revolutionary platform aims to make life-saving overdose reversal therapies more affordable, accessible, and effective worldwide
VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a dynamic holding company focused on innovative life sciences and wellness solutions, is thrilled to announce that its subsidiary, BioLegacy Evaluative Group Inc. ("BioLegacy"), has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for its groundbreaking intranasal drug delivery platform titled "Air-Driven Unitary Intranasal Drug Delivery Device for Stable and Reconstitutable Medicaments."
This cutting-edge technology marks a significant leap forward in nasal drug administration, tackling key challenges in emergency and self-administered pharmaceuticals. The compact, ergonomic, and air-powered device delivers precise, reliable, and cost-effective intranasal dosing for both stable liquid formulations—like naloxone for opioid overdose reversal—and lyophilized or unstable drugs that require on-demand reconstitution.
Key Innovations Driving the Platform:
- Air-Driven Precision Delivery – A compressible air chamber drives medication through a precision atomizer, ensuring complete and consistent dosing with minimal residual volume.
- Dual-Function Architecture – Accommodates both pre-formed stable solutions and unstable powder-based medicaments that are reconstituted seconds before use.
- Unitary Blow-Fill-Seal Construction – Manufactured as a single, sterile component minimizing contamination risk, assembly steps, and production cost.
- Sequential Frangible Membranes – Engineered rupture zones enable user-activated mixing and delivery through a simple one- or two-step squeeze mechanism.
- Ergonomic, Portable Design – Thumb-sized, single-use format ensures easy handling for untrained users in emergency scenarios.
The patent application describes two key embodiments: one supporting reconstitutable medicaments (such as lyophilized biologics or peptides requiring immediate mixing before use), and another optimized for stable solutions. Both versions deliver the medicament intranasally as a fine, uniform mist, ensuring rapid absorption and systemic effect.
"This filing represents a pivotal milestone for BioLegacy. Our air-driven intranasal device offers a scalable, globally manufacturable solution that overcomes cost, complexity, and stability barriers in emergency and routine drug delivery. It also directly supports our goal of democratizing access to affordable overdose-reversal therapies," said Amin Janmohamed, CEO.
Strategic Alignment and Next Steps
This patent aligns perfectly with BioLegacy's recent acquisition of a GMP-compliant manufacturing facility featuring ISO Class 7 & 8 cleanrooms and high-containment capabilities. The site will accelerate prototype testing, validation, and regulatory submissions to Health Canada and the FDA.
BLEG's R&D collaborations with McMaster University and Stanford University will continue to advance formulation, testing, and translational development of the inhaled naloxone program and other pipeline candidates leveraging this proprietary delivery system.
About BioLegacy Evaluative Group, Inc.
BioLegacy Evaluative Group Inc. is a life sciences company dedicated to developing innovative therapies and devices addressing urgent global health challenges. With strategic partnerships at McMaster University and Stanford University, and a newly acquired GMP-compliant manufacturing facility, BLEG is positioned to deliver scalable, cost-effective solutions in areas of high unmet need.
About Branded Legacy, Inc.
Branded Legacy, Inc. (OTC: BLEG) is a forward-thinking holdings company dedicated to pioneering solutions in addiction treatment and harm reduction. Through its subsidiary, BioLegacy Evaluative Group, and strategic collaborations with leading institutions like McMaster University and Stanford University, the company drives transformative research and innovation. With a state-of-the-art GMP manufacturing facility in Vancouver, Branded Legacy leverages advanced production capabilities to deliver cutting-edge products, positioning itself as a leader in addressing critical public health challenges.
Investor Relations:
Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.
FAQ
What is the new patent filed by Branded Legacy (BLEG) for?
What are the key features of BLEG's new intranasal delivery device?
How does BLEG's new intranasal device improve drug delivery?
What manufacturing capabilities does BLEG have for the new device?
Which research institutions is BLEG collaborating with?
